Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 35 Recurrence 27 Multiple Myeloma 27 Leukemia, Lymphocytic, Chronic, B-Cell 27 Lymphoma, Non-Hodgkin 25 Lymphoma 20 Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 16 Lymphoma, B-Cell 15 Lymphoma, Follicular 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Lymphoma, Mantle-Cell 13 Leukemia 13 Carcinoma, Non-Small-Cell Lung 13 Stomach Neoplasms 11 Ovarian Neoplasms 9 Pancreatic Neoplasms 8 Neoplasm Metastasis 8 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Head and Neck Neoplasms 7 Carcinoma, Renal Cell 7 Uterine Cervical Neoplasms 6 Myelodysplastic Syndromes 6 Melanoma 6 Lymphoma, B-Cell, Marginal Zone 6 Breast Neoplasms 6 Liposarcoma, Myxoid 5 Colorectal Neoplasms 5 Burkitt Lymphoma 5

Interventions

pembrolizumab 8 Pemetrexed 8 capmatinib 7 Carboplatin 7 ceritinib 5 Cisplatin 5 Bevacizumab 4 Docetaxel 3 trametinib 2 motexafin gadolinium 2 aldesleukin 2 Vinorelbine 2 Paclitaxel 2 Interleukin-2 2 Gefitinib 2 BID protein, human 2 technetium 99m etarfolatide 1 spartalizumab 1 sintilimab 1 satraplatin 1 ribociclib 1 picropodophyllin 1 nazartinib 1 naporafenib 1 milademetan 1 lazertinib 1 fludarabine phosphate 1 fludarabine 1 farletuzumab 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenocarcinoma of Lung × fludarabine × Clear all

NCT05566223 2026-02-23

CheckCell-2

Intima Bioscience, Inc.

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡